Talk:Mecasermin rinfabate

Nice start
Nice start. Thanks for putting this up69.134.50.67 15:51, 17 May 2007 (UTC)

Thanks for this page. I have edited the ALS section, adding information from a peer-reviewed article in "Neurology" about the recent trial on subcutaneous IGF-1.

I was concerned about the line that was previously in this article: " IPLEX is the first drug of any kind to show effectiveness in reducing the symptoms of ALS."

This line was unreferenced but I found it on a nurse's blog http://rarediseases.about.com/b/2008/11/18/insmed-genentech-and-ipsentercica-issue-statement-about-iplex-for-als.htm It is especially inaccurate and there is no peer-reviewed evidence to back it up. Some of my own patients have already come across this line and were misled by it, especially given the recent trial results. I hope that this page can nonetheless emphasise that IGF-1 may very well play an important role in ALS, just not in the subcutaneous route.

As the ALS association have said “These results are deeply disappointing to all of us in the ALS community,” said Lucie Bruijn, Ph.D., senior vice president, research and development, The ALS Association. “The subcutaneous delivery route may be the key problem, or it may be that IGF-1 alone is not sufficient to rescue motor neurons.”. http://www.alsa.org/news/article.cfm?id=1384&CFID=2282201&CFTOKEN=a7d618d06d46667d-0C1C7E6F-188B-2E62-80B63429A87E3E0D —Preceding unsigned comment added by ALS Researcher (talk • contribs) 12:31, 6 December 2008 (UTC)

- ALS Researcher, in the above comments, has confused mecasermin rinfabate (rhIGF-1/IGFBP-3, branded as Iplex) with mecasermin (rhIGF-1, branded as Increlex). The inability of free rhIGF-1 to deliver a meaningful availability of IGF-1 to benefit ALS sufferers does NOT equate to a similar inability of rhIGF-1/IGFBP-3 to do so. And it must be clarified that the failure of the rhIGF-1 trials in ALS is suspected to be due to any of several factors of DELIVERY - including formulaic-, and not simply the mode of administration. Subcutaneous administration of other formulations to deliver IGF-1 still show promise. One such formulation is a non-pathogenic viral delivery of IGF1-inducing gene sequences. , . Another promising means of delivering IGF-1 is subcutaneous administration of mecasermin rinfabate (rhIGF-1/IGFBP-3). No clinically controlled study of mecasermin rinfabate in ALS has taken place, but the drug has been found to be well tolerated in humans [FDA Full Report on Iplex for Severe Primary IGFD, 2006], with greater IGF-1 bioavailability, and less incidence of dose-limiting side effects than what users of rhIGF-1 have experienced , , [FDA Centerwatch, 2006]. Efforts are underway to fund an ALS trial of subcutaneously administered mecasermin rinfabate. May 17, 2011 PDT. —Preceding unsigned comment added by Jessbertrand (talk • contribs) 03:17, 18 May 2011 (UTC)

External links modified (January 2018)
Hello fellow Wikipedians,

I have just modified one external link on Mecasermin rinfabate. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
 * Added tag to http://www.informapharmascience.com/doi/abs/10.1517/17425255.4.3.311
 * Added archive https://web.archive.org/web/20160303235644/http://www.informapharmascience.com/doi/abs/10.1517/13543784.15.4.409 to http://www.informapharmascience.com/doi/abs/10.1517/13543784.15.4.409

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

Cheers.— InternetArchiveBot  (Report bug) 22:33, 23 January 2018 (UTC)